HA35

PreclinicalSmall molecule

NNakhia Impex LLC

HA35 is one of 35 small molecule programs targeting Myofascial Pain Syndrome. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myofascial Pain SyndromeActive, not recruiting

Rectal CancerCompleted

Myofascial Pain SyndromePreclinical

Active, not recruiting

Rectal CancerPreclinical

Completed

Competition

Competitive Landscape

33 competitors in Rectal Cancer

#DrugCompanyPhaseTrials

Eloxatin

Teva

Phase 3

22 2

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

29 3

Adrucil

EElorac, Inc.

Phase 3

6 4

Wellcovorin

GGlaxo Dba Glaxosmithkline

Phase 3

5 5

Capeox

GSK

Phase 3

2 6

Keytruda

Merck & Co.

Phase 2

2 7

Stivarga

Bayer

Phase 2

2 8

Opdivo

Bristol-Myers Squibb

Phase 2

1 9

Herceptin

Roche

Phase 2

1 10

Tukysa

Pfizer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rectal Cancer1 trial

35kDa Hyaluronan Fragment Treatment of Colorectal and Rectal Cancer

Completed·NNakhia Impex LLC·N/A·NCT06209970·10 enrolled

Chronic Wound1 trial

35kDa Hyaluronan Fragment Injection Treatment Myofascial Pain Syndrome

Completed·NNakhia Impex LLC·Preclinical·NCT06444035·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for HA35. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HA35 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HA35. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nakhia Impex LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNakhia Impex LLC

HA35

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rectal Cancer1 trial

Chronic Wound1 trial

References

Drug Info

Quick Facts

Related News